The boom in digital tech over COVID means that pharma can move faster than ever – but the industry’s traditional processes for asset approval are still holding timelines back.
Gastroenterologist Dr Séverine Vermeire explains how lockdowns and communication changes over COVID-19 are taking their toll on ulcerative colitis patients and how we can best support them
